JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB256846

Human B2M (beta 2 Microglobulin) knockout Hep G2 cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

B2M KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1 and Insertion of the selection cassette in exon1.

View Alternative Names

B2M, B2MG_HUMAN, Beta 2 microglobin, Beta 2 microglobulin, Beta 2 microglobulin precursor, Beta chain of MHC class I molecules, Beta chain of mhc class 1 proteins, Beta-2-microglobulin form pI 5.3, CDABP0092, Hdcma22p, IMD43

4 Images
Western blot - Human B2M (beta 2 Microglobulin) knockout Hep G2 cell lysate (AB256846)
  • WB

Lab

Western blot - Human B2M (beta 2 Microglobulin) knockout Hep G2 cell lysate (AB256846)

Lane 1 : Wild-type HepG2 cell lysate (20 ug)
Lane 2 : B2M knockout HepG2 cell lysate (20 ug)
Lane 3 : HeLa cell lysate (20 ug)
Lane 4 : Jurkat cell lysate (20 ug)

ab75853 was shown to specifically react with beta 2 Microglobulin in wild-type HepG2 cells. Loss of signal was observed when knockout cell line ab262325 (knockout cell lysate ab256846) was used. Wild-type and beta 2 Microglobulin knockout samples were subjected to SDS-PAGE. ab75853 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4oC at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-beta 2 Microglobulin antibody [EP2978Y] (<a href='/en-us/products/primary-antibodies/beta-2-microglobulin-antibody-ep2978y-ab75853'>ab75853</a>) at 1/1000 dilution

Lane 1:

Wild-type HepG2 cell lysate at 20 µg

Lane 2:

B2M knockout HepG2 cell lysate at 20 µg

Lane 2:

Western blot - Human B2M (beta 2 Microglobulin) knockout Hep G2 cell line (<a href='/en-us/products/cell-lines/human-b2m-beta-2-microglobulin-knockout-hep-g2-cell-line-ab262325'>ab262325</a>)

Lane 3:

HeLa cell lysate at 20 µg

Lane 4:

Jurkat cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/10000 dilution

Predicted band size: 14 kDa

Observed band size: 14 kDa

false

Western blot - Human B2M (beta 2 Microglobulin) knockout Hep G2 cell lysate (AB256846)
  • WB

Lab

Western blot - Human B2M (beta 2 Microglobulin) knockout Hep G2 cell lysate (AB256846)

Lane 1 : Wild-type HepG2 cell lysate (20 ug)
Lane 2 : B2M knockout HepG2 cell lysate (20 ug)
Lane 3 : HeLa cell lysate (20 ug)
Lane 4 : Jurkat cell lysate (20 ug)

ab218230 was shown to specifically react with beta 2 Microglobulin in wild-type HepG2 cells. Loss of signal was observed when knockout cell line ab262325 (knockout cell lysate ab256846) was used. Wild-type and beta 2 Microglobulin knockout samples were subjected to SDS-PAGE. ab218230 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4oC at 1 in 500 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-beta 2 Microglobulin antibody [EPR21752-214] (<a href='/en-us/products/primary-antibodies/beta-2-microglobulin-antibody-epr21752-214-ab218230'>ab218230</a>) at 1/500 dilution

Lane 1:

Wild-type HepG2 cell lysate at 20 µg

Lane 2:

B2M knockout HepG2 cell lysate at 20 µg

Lane 3:

HeLa cell lysate at 20 µg

Lane 4:

Jurkat cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/10000 dilution

Predicted band size: 14 kDa

Observed band size: 14 kDa

false

Sanger Sequencing - Human B2M (beta 2 Microglobulin) knockout Hep G2 cell lysate (AB256846)
  • Sanger seq

Unknown

Sanger Sequencing - Human B2M (beta 2 Microglobulin) knockout Hep G2 cell lysate (AB256846)

Allele-1 : 1 bp insertion in exon1

Sanger Sequencing - Human B2M (beta 2 Microglobulin) knockout Hep G2 cell lysate (AB256846)
  • Sanger seq

Unknown

Sanger Sequencing - Human B2M (beta 2 Microglobulin) knockout Hep G2 cell lysate (AB256846)

Allele-2 : Insertion of the selection cassette in exon1

Key facts

Cell type

Hep G2

Species or organism

Human

Tissue

Liver

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1 and Insertion of the selection cassette in exon1.

Disease

Hepatocellular Carcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab256846-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human wild-type HepG2 cell lysate", "number":"AB256846-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human B2M knockout HepG2 cell lysate", "number":"AB256846-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
B2M
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Beta-2-Microglobulin (B2M) is a component of the class I major histocompatibility complex (MHC I) and plays an important role in presenting peptides to the immune system. B2M weighs approximately 11.8 kDa and is found abundantly in all nucleated cells. It has alternate names such as B2 microglobulin or beta-2-microglobulin. This protein is present in the cell membrane as a part of the MHC I which is important for immune surveillance. Additionally B2M is detectable in various biological fluids including serum and its levels can reflect physiological and pathological states.
Biological function summary

Beta-2-microglobulin is important for the stability and transport of MHC class I molecules to the cell surface. As part of the MHC class I complex B2M assists in binding peptides allowing immune cells to identify and target pathogen-infected cells. Without B2M the MHC class I molecules are not properly expressed on the cell surface disrupting immune recognition. In laboratory settings researchers often use anti-beta-2-microglobulin antibodies to investigate its role in MHC class I function.

Pathways

Beta-2-microglobulin interacts significantly with the immune system most notably in the antigen processing and presentation pathway. It works alongside proteins such as the heavy chain of MHC class I. B2M is important in the pathway that involves the transport of antigens to the endoplasmic reticulum where they are loaded onto MHC class I molecules for inspection by cytotoxic T cells. Another related pathway is the tapasin-mediated processing of antigen peptides highlighting the indispensable role of B2M in immune response regulation.

Beta-2-microglobulin is associated with conditions such as beta-2-microglobulin amyloidosis and certain lymphoproliferative disorders. Elevated levels of B2M in serum serve as a marker for diseases like multiple myeloma where the protein level correlates with disease severity. B2M-related amyloidosis frequently occurs in patients undergoing long-term dialysis where amyloid deposits accumulate in tissues. Linking B2M to immune system dysfunction studies have shown interactions with other proteins including components of the immune system like HLA-A and HLA-B highlighting B2M's relevance in diagnosing and understanding these conditions.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com